Dashboard
Manage Tickers

ADCT


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-maintains-buy-on-adc-therapeutics-lowers-price-target-to-7
HC Wainwright & Co. Maintains Buy on ADC T...
10/16/2025 11:24:04

HC Wainwright & Co. analyst Robert Burns maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target f...

adc-therapeutics-announces-60m-private-placement-co-to-sell-113m-common-shares-at-4share-and-pre-funded-warrants-at-390share
ADC Therapeutics Announces $60M Private Pl...
10/13/2025 11:35:49

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
10/02/2025 21:06:15

top-5-biotech-stocks-with-strong-momentum
Top 5 Biotech Stocks With Strong Momentum
08/28/2025 11:19:00

Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies.

guggenheim-reiterates-buy-on-adc-therapeutics-maintains-10-price-target
Guggenheim Reiterates Buy on ADC Therapeut...
08/13/2025 13:47:04

Guggenheim analyst Michael Schmidt reiterates ADC Therapeutics (NYSE:ADCT) with a Buy and maintains $10 price target.

adc-therapeutics-q2-adj-eps-025-beats-039-estimate-sales-18839m-beat-17776m-estimate
ADC Therapeutics Q2 Adj. EPS $(0.25) Beats...
08/12/2025 11:31:00

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.39...

Core News & Articles
Earnings Scheduled For August 12, 2025
08/12/2025 08:32:28

preview-adc-therapeuticss-earnings
Preview: ADC Therapeutics's Earnings
08/11/2025 19:03:51

rbc-capital-maintains-outperform-on-adc-therapeutics-lowers-price-target-to-5
RBC Capital Maintains Outperform on ADC Th...
06/20/2025 13:55:48

RBC Capital analyst Leonid Timashev maintains ADC Therapeutics (NYSE:ADCT) with a Outperform and lowers the price target fro...

adc-therapeutics-to-present-updated-data-from-phase-2-multicenter-iit-of-zynlonta-to-treat-rr-mzl-at-international-conference-on-malignant-lymphoma
ADC Therapeutics To Present Updated Data F...
06/16/2025 11:17:07

Updated Phase 2 data evaluating ZYNLONTA® as a monotherapy demonstrate overall response rate (ORR) of 85% and complete response...

guggenheim-maintains-buy-on-adc-therapeutics-raises-price-target-to-10
Guggenheim Maintains Buy on ADC Therapeuti...
06/13/2025 14:14:19

Guggenheim analyst Michael Schmidt maintains ADC Therapeutics (NYSE:ADCT) with a Buy and raises the price target from $7 to ...

adc-therapeutics-raises-100m-in-private-stock-deal-of-13m-shares-at-35share-and-warrants-to-purchase-157m-shares-at-343pre-funded-warrant-to-boost-cancer-drug-development
ADC Therapeutics Raises $100M in Private S...
06/12/2025 10:51:37

ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), ...

adc-therapeutics-reports-93-response-rate-in-lymphoma-drug-trial-including-car-t-resistant-patients
ADC Therapeutics Reports 93% Response Rate...
06/12/2025 10:35:20

ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), ...

rbc-capital-reiterates-outperform-on-adc-therapeutics-maintains-8-price-target
RBC Capital Reiterates Outperform on ADC T...
05/15/2025 15:46:01

RBC Capital analyst Gregory Renza reiterates ADC Therapeutics (NYSE:ADCT) with a Outperform and maintains $8 price target.

adc-therapeutics-q1-adj-eps-022-beats-040-estimate-sales-2303m-beat-1771m-estimate
ADC Therapeutics Q1 Adj. EPS $(0.22) Beats...
05/14/2025 12:04:24

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.40...

adc-therapeutics-presents-data-from-lotis-7-phase-1b-clinical-trial-evaluating-zynlonta-in-combination-with-glofitamab-in-patients-with-rr-dlbcl
ADC Therapeutics Presents Data From LOTIS-...
05/14/2025 11:47:37

ZYNLONTA® plus glofitamab (COLUMVI®) demonstrated ORR of 95.5% and CR of 90.9%, among 22 evaluable patients with relapsed/refra...

Core News & Articles
Earnings Scheduled For May 14, 2025
05/14/2025 08:32:23

preview-adc-therapeuticss-earnings
Preview: ADC Therapeutics's Earnings
05/13/2025 19:04:36

adc-therapeutics-claudin-6-targeting-adc-shows-strong-single-agent-and-combination-potential-in-solid-tumors
ADC Therapeutics' Claudin-6 Targeting ADC ...
04/28/2025 11:09:54

Oral presentation shows ADCT-242 targeting Claudin-6 was well-tolerated and demonstrated potent antitumor activity in ovarian a...

guggenheim-maintains-buy-on-adc-therapeutics-lowers-price-target-to-7
Guggenheim Maintains Buy on ADC Therapeuti...
03/31/2025 13:54:02

Guggenheim analyst Michael Schmidt maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target from $10 to...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION